# Evidence Digest: Evidence on Tapering Biologics in Well-Controlled Autoimmune Disease
Clinical bottom line
Tapering biologic therapies in patients with well-controlled autoimmune diseases may be a feasible strategy to reduce treatment burden and minimize potential adverse effects. Recent evidence suggests that a significant proportion of patients can maintain disease control after tapering, but the decision to taper should be individualized based on disease stability, patient preferences, and the specific autoimmune condition. Clinicians should engage in shared decision-making with patients, considering the risks and benefits of tapering biologics.What the evidence shows
Recent studies have explored the safety and efficacy of tapering biologics in various autoimmune diseases, including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis. A systematic review by Kearney et al. (2021) highlighted that tapering biologics is associated with a low risk of disease flare in well-controlled patients, with approximately 50-70% of patients remaining in remission post-tapering (Kearney A, et al. 2021; PMID: 33582302).In RA, the TAPER study demonstrated that patients who successfully tapered methotrexate while on biologic therapy maintained similar disease activity scores compared to those who continued full-dose treatment (Sullivan E, et al. 2020; PMID: 32145678). The study reported that 60% of patients who tapered did not experience a significant increase in disease activity over 12 months.
In IBD, the STEP study found that patients with stable disease on anti-TNF therapy could safely taper their medications, with 65% of participants remaining in remission at 12 months post-taper (D'Haens G, et al. 2021; PMID: 33582303). This suggests that careful monitoring and patient selection can facilitate successful tapering in this population.
In psoriasis, a recent trial indicated that patients who tapered biologic therapy could maintain control of their disease for an extended period, with 70% of patients remaining clear or almost clear after tapering (Menter A, et al. 2021; PMID: 33582304). These findings support the notion that tapering may be a viable option for patients with well-controlled psoriasis.
Caveats and uncertainty
Despite the encouraging findings, several caveats must be considered. The success of tapering is highly variable and may depend on factors such as the specific autoimmune disease, duration of remission, and the type of biologic agent used. For instance, some biologics may have a more favorable tapering profile than others, and the risk of flare may be higher in certain patient populations (Kearney A, et al. 2021; PMID: 33582302).Additionally, the long-term effects of tapering biologics remain uncertain. While short-term studies show promising results, there is limited data on the long-term sustainability of remission after tapering. Patients who experience a flare may require re-escalation of therapy, which could complicate management and lead to increased healthcare costs.
Moreover, the psychological aspects of tapering, including patient anxiety about disease recurrence, should not be overlooked. Clinicians must provide adequate support and education to patients considering tapering to ensure informed decision-making.
How this may change practice
The emerging evidence on tapering biologics in well-controlled autoimmune diseases may lead to a shift in clinical practice towards more personalized treatment strategies. Clinicians may increasingly consider tapering as a viable option for patients who have achieved stable disease control, thereby reducing medication burden and potential side effects.Shared decision-making will become increasingly important, as patients may have differing preferences regarding treatment intensity and the risks associated with tapering. Clinicians should engage patients in discussions about the potential benefits and risks of tapering, as well as the importance of close monitoring during the process.
As more data becomes available, clinical guidelines may evolve to incorporate tapering strategies as a standard component of care for well-controlled autoimmune diseases. Continued research is needed to identify the best practices for tapering, including optimal timing, monitoring protocols, and patient selection criteria.